156 related articles for article (PubMed ID: 32814048)
1. Fyn Kinase Controls Tau Aggregation In Vivo.
Briner A; Götz J; Polanco JC
Cell Rep; 2020 Aug; 32(7):108045. PubMed ID: 32814048
[TBL] [Abstract][Full Text] [Related]
2. Fyn depletion ameliorates tau
Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
Acta Neuropathol Commun; 2020 Jul; 8(1):108. PubMed ID: 32665013
[TBL] [Abstract][Full Text] [Related]
3. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
Li C; Götz J
EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
[TBL] [Abstract][Full Text] [Related]
4. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
5. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
Xia D; Li C; Götz J
Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
[TBL] [Abstract][Full Text] [Related]
6. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Li C; Götz J
J Alzheimers Dis; 2018; 64(1):205-221. PubMed ID: 29782321
[TBL] [Abstract][Full Text] [Related]
7. Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.
Lau DH; Hogseth M; Phillips EC; O'Neill MJ; Pooler AM; Noble W; Hanger DP
Acta Neuropathol Commun; 2016 May; 4(1):49. PubMed ID: 27193083
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology.
Shen LL; Li WW; Xu YL; Gao SH; Xu MY; Bu XL; Liu YH; Wang J; Zhu J; Zeng F; Yao XQ; Gao CY; Xu ZQ; Zhou XF; Wang YJ
Neurobiol Dis; 2019 Dec; 132():104567. PubMed ID: 31394202
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
10. A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.
Rush T; Roth JR; Thompson SJ; Aldaher AR; Cochran JN; Roberson ED
Neurobiol Dis; 2020 Feb; 134():104668. PubMed ID: 31698056
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
Roberson ED; Halabisky B; Yoo JW; Yao J; Chin J; Yan F; Wu T; Hamto P; Devidze N; Yu GQ; Palop JJ; Noebels JL; Mucke L
J Neurosci; 2011 Jan; 31(2):700-11. PubMed ID: 21228179
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
[TBL] [Abstract][Full Text] [Related]
13. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.
Miyamoto T; Stein L; Thomas R; Djukic B; Taneja P; Knox J; Vossel K; Mucke L
Mol Neurodegener; 2017 May; 12(1):41. PubMed ID: 28526038
[TBL] [Abstract][Full Text] [Related]
15. Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo.
Vasconcelos B; Stancu IC; Buist A; Bird M; Wang P; Vanoosthuyse A; Van Kolen K; Verheyen A; Kienlen-Campard P; Octave JN; Baatsen P; Moechars D; Dewachter I
Acta Neuropathol; 2016 Apr; 131(4):549-69. PubMed ID: 26739002
[TBL] [Abstract][Full Text] [Related]
16. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Tang SJ; Fesharaki-Zadeh A; Takahashi H; Nies SH; Smith LM; Luo A; Chyung A; Chiasseu M; Strittmatter SM
Acta Neuropathol Commun; 2020 Jul; 8(1):96. PubMed ID: 32611392
[TBL] [Abstract][Full Text] [Related]
17. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
18. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
Kaufman SK; Del Tredici K; Thomas TL; Braak H; Diamond MI
Acta Neuropathol; 2018 Jul; 136(1):57-67. PubMed ID: 29752551
[TBL] [Abstract][Full Text] [Related]
19. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
20. Disease-related modifications in tau affect the interaction between Fyn and Tau.
Bhaskar K; Yen SH; Lee G
J Biol Chem; 2005 Oct; 280(42):35119-25. PubMed ID: 16115884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
